

### PERSONAL INFORMATION

Elena Morejon

### WORK EXPERIENCE

---

June 2016- Present

#### Clinical Assesor

Spanish Agency for Medicines and Health Products (Spain)

Participation in the following activities of ophtalmology, anaesthesia, neurology and genitourinary therapeutic areas:

- European (centralised, decentralised and mutual recognition) and National registration procedures and variations for medicinal products for human use
- National Therapeutic positioning reports for medicinal products for human use
- Scientific advices for medicinal products for human use

February 2016-May 2016

#### Medical Manager

Astra Zeneca Spain (Spain)

Participation in the following Medical Affairs activites (diabetes área):

- Design and implementation the medical strategy of the area/products under his/her responsibility
- Regional/local clinical studies
- Advisory Boards, Medical Education, Congresses, Scientific meetings
- Medical input and oversight of Marketing/Commercial activities/plans
- Medical support to Regulatory, Safety, Pharmacoeconomics/Market Access and Bussiness Development Departments
- Medical Governance/Risk Management
- Medical Training to other Departments
- Interaction with Health Care Proffesionals and Medical Societies
- Budgetary control

October 2011-June 2015

#### Therapy Area Medical Director

GlaxoSmithKline Spain (Spain)

Oversight and participation in the following Medical Affairs/Clinical Research activites (respiratory, immuno-inflammation, infectious, dermatology, rare diseases, cardiovascular, neurosciences, gastrointestinal, oncology):

- Design and implementation of the medical strategy of the area/products under his/her responsibility
- Management of clinical studies (registration, regional and local)
- Advisory Boards, Medical Education, Congresses, Scientific meetings
- Medical input and oversight of Marketing/Commercial activities/plans
- Medical support to Regulatory, Safety, Pharmacoeconomics/Market Access and Bussiness Development Departments
- Compassionate use programs
- Medical Governance/Risk Management
- Medical Training to other Departments
- Interaction with Health Care Proffesionals and Medical Societies
- Budgetary control

February 2001-September 2011

#### Medical Operations Manager / Director

GlaxoSmithKline Spain (Spain)

Oversight and participation in the following Medical Department activities (mainly but not only clinical research):

- Medical Governance,/Risk Management
- Quality control and audits
- Standard Operating Practices and Training
- Outsourcing management

-Compassionate uses

April 1999-January 2001

### Head of Clinical Research and Pharmacovigilance

GlaxoWellcome Spain (Spain)

Oversight and participation in the following clinical research and pharmacovigilance activities:

- Implementation and conduct of R&D and regional/local studies ensuring the best standards
- Medical Governance,/Risk Management
- Quality control and audits
- Standard Operating Practices and Training
- Outsourcing management
- Management of pharmacovigilance for investigational and marketed products according to regulatory requirements and Company standard procedures

October 1995-March 1999

### Therapy Area Medical Manager

GlaxoWellcome Spain (Spain)

September 1990-September 1995

### Therapy Area Medical Manager

Glaxo Spain (Spain)

## EDUCATION AND TRAINING

---

1979- 1985

### Medical Degree (MD) in Medicine and Surgery

University Complutense of Madrid ()

1990- 1992

### Universitary Specialist in Pharmaceutical Medicine

University Complutense of Madrid ()

1998- 1999

### Executive Development Programme

IESE Business School University of Navarra ()

1986- 1988

### Research Ability Certificate (Preventive Medicine and Public Health)

University Complutense of Madrid ()

## ADDITIONAL INFORMATION

---

### Expertise

#### Publications

1. "Asma en el anciano. Características clínicas, económicas y de la calidad de vida". Archivos de Bronconeumología 1997; 3 (1): 70.
2. "Usefulness of the St. George Respiratory Questionnaire according to asthma severity". European Respiratory Journal 1997, 10 (Supp. 25): 364s: P2224.
3. "Quality of life and economic features of the elderly asthmatics". European Respiratory Journal 1997, 10 (Supp. 25): 226s: P1465.
4. "Características clínicas y morbilidad en el asma estable. Analisis descriptivo del asma en una comunidad mediterranea". Archivos de Bronconeumología 1997; 33: 457-461.
5. "Costs of asthma according to the degree of severity". European Respiratory Journal 1998; 12: 1322-6.
6. "Patient learning ability and preference for either of two different multidose dry powder inhaler devices". European Respiratory Journal 1999; 14 (Supp. 30): 60s: P466.
7. "Quality of Life and Economic Features in Elderly Asthmatics". Respiration 2000; 67: 65-70.
8. "Patient Perception and Acceptability of Multidose Dry Powder Inhalers: A randomised crossover comparison of Diskus/Accuhaler with Turbuhaler". Journal of Aerosol Medicine 2002; 15 (1): 59-64.
9. "Nature and extent of changes in the patient's information sheets of internacional multicentre clinical trials as requested by Spanish Research Ethics Committees. Medicina Clinica (Barc) 2004; 123 (20): 770-774.

10. "Multicentre trials review process by research ethics committees in Spain: where do they stand before implementing the new European regulation? Journal of Medical Ethics 2005; 31: 344-350.
11. "¿Cual es el tiempo minimo necesario para iniciar un ensayo clinico multicentrico en Espana?" Medicina Clinica (Barcelona) 2007; 128 (7): 275.
12. "Uso de recursos y costes asociados al asma y la EPOC: estudio retrospectivo de base poblacional". Archivos de Bronconeumologia 2013; 49: 126.
13. "Healthcare resouces utilization and associated costs in patients with COPD with or without asthma: a retrospective, population-based observational study". Value in Health 2013; 16 (7): A370.
14. "Evolution of Patients with Systemic Lupus Erythematosus Treated with Belimumab in Clinical Practice Settings". Arthritis Rheumatology. 2014; 66(Supplement): S291.
15. "Does the COPD Assessment test (CAT) questionnaire produce similar results when self-or interviewer-administered?". Quality of Life Research 2015; 24 (10): 2345-54.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)